2 completed, 2 recruiting, 2 withdrawn, 1 active not recruiting. 9 Phase 1, 4 Phase 2.
Follow Extensive-stage Small-cell Lung Cancer: new trials by email Literature Review of Extensive-stage Small-cell Lung Cancer trials Research Report on Extensive-stage Small-cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer Valemetostat, Atezolizumab - Extensive-stage Small-cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2025-01-29 | 2026-11-02 |
| Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC Low-dose radiotherapy, Tifcemalimab injection, Toripalimab - Extensive-stage Small-cell Lung Cancer | Phase 1 | Withdrawn | Sichuan University | 2025-01-10 | 2026-04-29 | |
| An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer Radioconjugate, Positron Emission Tomography, Computed Tomography - Extensive-stage Small-cell Lung Cancer, Limited-stage Small-cell Lung Cancer | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2024-10-01 | 2024-09-27 | |
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC Low-dose radiotherapy, Etoposide, Cisplatin - Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan University | 45 | 2024-04-18 | 2026-05-05 |
| Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy Adebrelimab, Irinotecan Liposome (II), Adebrelimab, Irinotecan Liposome (II), Famitinib - Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Baohui Han | 80 | 2024-04-01 | 2024-03-27 |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies 23ME-00610 - Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | 23andMe, Inc. | 141 | 2021-12-29 | 2024-11-15 |
| Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors RP12146 - Solid Tumor, Extensive-stage Small-cell Lung Cancer | Phase 1 | Completed | Rhizen Pharmaceuticals SA | 23 | 2021-10-05 | 2024-09-19 |
| Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer Carfilzomib, Carboplatin, Etoposide - Extensive-Stage Small-Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Amgen | 32 | 2013-11-05 | 2017-08-28 |
Small Cell Lung Carcinoma (9) · Lung Neoplasms (3) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Fallopian Tube Neoplasms (1) · Neuroendocrine Tumors (1)
Bronchial Neoplasms (9) · Carcinoma, Bronchogenic (9) · Lung Diseases (9) · Neoplasms (9) · Neoplasms by Site (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9) · Thoracic Neoplasms (9) · Lung Neoplasms (6) · Adenocarcinoma (1) · Adnexal Diseases (1) · Breast Diseases (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Etoposide (4) · Carboplatin (3) · Cisplatin (3) · Radiotherapy (2) · ADP Ribose Transferases (1) · Magnetic Resonance Spectroscopy (1) · Platinum (1) · Radiosurgery (1) · atezolizumab (1) · carfilzomib (1) · durvalumab (1) · famitinib (1) · irinotecan sucrosofate (1) · olaparib (1) · sugemalimab (1)
Sichuan University (2) · 23andMe, Inc. (1) · Amgen (1) · Baohui Han (1) · Memorial Sloan Kettering Cancer Center (1) · Rhizen Pharmaceuticals SA (1) · Roswell Park Cancer Institute (1) · University of Maryland, Baltimore (1)
United States (4) · Canada (2) · China (2) · Czechia (1) · Poland (1) · Russia (1)
Grace Dy, MD (1) · Jessica Ross, MD (1) · Taofeek Owonikoko, MD, PhD (1) · You Lu, MD (1)